Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Response Genetics Appoints Company President

This article was originally published in Scrip

Executive Summary

Los Angeles-based Response Genetics, a company developing and commercialising molecular diagnostic tests for cancer has appointed Christine Meda as the new company president. Ms Meda brings nearly 30 years of know-how in strategic partnering, operations, and marketing to her role at Response. She also founded and is still president of RxDxLink, a consultancy advising early stage biotechnology firms.

You may also be interested in...

Cellerant adds two new management components

Cellerant Therapeutics, a biotechnology company which specialises in therapies for blood disorders, has appointed Dr Margaret Dillon as vice president of regulatory affairs and Dr Robert Tressler as vice president of research and development. Dr Dillon comes to Cellerant with 19 years of experience in pharmaceutical regulatory affairs, most recently with CV Therapeutics (now Gilead Sciences). Dr Tressler brings to the table 20 years of industry experience in oncology, cardiovascular and immunological indications. Most recently, he served as executive director of research for Geron.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts